Anna Squadrilli
Parma, 43126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Journal: Cancers
Published: September 15, 2021
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.
Journal: Frontiers in oncology
Published: April 27, 2021
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report.
Journal: Translational lung cancer research
Published: July 18, 2020
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 05, 2020
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Journal: Therapeutic advances in medical oncology
Published: April 09, 2020
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
Journal: Immunotherapy
Published: February 19, 2020
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Journal: Therapeutic advances in medical oncology
Published: April 05, 2019
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 18, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 09, 2019
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer.
Journal: Oncology reports
Published: October 10, 2018
Last Updated: 09/26/2026